Welcome to our dedicated page for Zai Lab news (Ticker: ZLAB), a resource for investors and traders seeking the latest updates and insights on Zai Lab stock.
Zai Lab Limited (ZLAB) is a research-based, commercial-stage biopharmaceutical company based in China and the United States, with a focus on oncology, immunology, neuroscience, and infectious disease. The Zai Lab news feed on Stock Titan aggregates company announcements, clinical updates, regulatory milestones, and financial disclosures that the company releases through channels such as Business Wire and SEC filings.
Investors and followers of ZLAB stock can use this page to review news on Zai Lab’s global pipeline, including progress of assets like zocilurtatug pelitecan (zoci), a DLL3-targeted antibody-drug conjugate for extensive-stage small cell lung cancer and other neuroendocrine carcinomas, and ZL-1503, an IL-13/IL-31R bispecific antibody for atopic dermatitis. Updates on other oncology and immunology programs, such as ZL-6201, ZL-1222, and ZL-1311, also appear in company press releases.
The news stream highlights regulatory developments in Greater China, including National Medical Products Administration (NMPA) approvals and National Reimbursement Drug List (NRDL) decisions for products in Zai Lab’s commercial portfolio. Recent examples include announcements about COBENFY for schizophrenia and AUGTYRO for ROS1-positive non-small cell lung cancer and NTRK-positive solid tumors, as well as renewals and coverage decisions for VYVGART, NUZYRA, and ZEJULA.
In addition, this page surfaces Zai Lab’s financial result releases, conference call notices, and participation in healthcare and investor conferences. These items provide context on revenue trends, R&D spending, and the company’s dual-engine strategy combining a China commercial business with a global innovation platform. Bookmark this page to quickly access ZLAB-related news, organized in one place for efficient review of the company’s ongoing clinical, regulatory, and corporate developments.
Zai Lab Limited (NASDAQ: ZLAB) reported significant advancements in its clinical pipeline and financial results for the six months ending June 30, 2020. The company achieved net product revenues of $19.2 million, driven by ZEJULA and Optune sales. With two successful launches, NMPA approval for Optune, and three NDAs accepted for priority review, Zai Lab is positioned for growth. Despite a net loss of $128.6 million, the company has $464.1 million in cash, supporting ongoing R&D and commercialization efforts. A conference call is scheduled for today at 8:00 a.m. EDT.
On August 4, 2020, Zai Lab (NASDAQ: ZLAB) announced that China's NMPA has granted priority review for the New Drug Application of ripretinib, aimed at adult patients with advanced gastrointestinal stromal tumors (GIST) who have failed three or more kinase inhibitors. This status highlights the unmet need for over 30,000 new GIST cases annually in China. Ripretinib targets a broad range of KIT and PDGFRα mutations, showing potential to transform GIST treatment. The drug is already approved in the U.S., Canada, and Australia under the brand name QINLOCK™.
Zai Lab Limited (NASDAQ: ZLAB) announced it will report financial results for the six months ending June 30, 2020, and provide corporate updates on August 13, 2020, before the market opens. The company will host a live conference call and webcast at 8:00 a.m. ET on the same day, requiring prior registration. Zai Lab focuses on innovative biopharmaceutical solutions for cancer, infectious, and autoimmune diseases, targeting the Chinese pharmaceutical market with a robust pipeline through global partnerships.
Zai Lab Limited (NASDAQ: ZLAB) has announced that the China National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for ripretinib, aimed at treating adult patients with advanced gastrointestinal stromal tumor (GIST) after prior treatments with multiple kinase inhibitors. Following the recent U.S. FDA approval, ripretinib shows potential to address a significant unmet medical need in China, where over 30,000 new GIST cases are diagnosed annually. The INVICTUS trial results demonstrate ripretinib's efficacy, significantly improving progression-free and overall survival rates.
Zai Lab Limited (NASDAQ: ZLAB) announced positive topline results from the NORA study, a Phase 3 trial evaluating ZEJULA (niraparib) as maintenance therapy in Chinese patients with recurrent ovarian cancer. The study, the largest of its kind in China, randomized 265 patients and met its primary endpoint of statistically significant improvement in progression-free survival. Additionally, the individualized starting dose regimen improved safety, showing lower rates of anemia and thrombocytopenia. This study aligns with results from the global NOVA study, reinforcing ZEJULA's potential in clinical practice.
Zai Lab Limited (NASDAQ: ZLAB) announced its participation in three upcoming virtual conferences in June. Dr. Samantha Du, the CEO, will present at the Jefferies Global Healthcare Conference on June 2, the Goldman Sachs Annual Global Healthcare Conference on June 11, and participate in a panel at the JP Morgan China Investor Conference on June 24. Webcasts will be available live and archived on Zai Lab's website. The company focuses on developing medicines for cancer, infectious, and autoimmune diseases, aiming to establish a global pipeline of innovative drug candidates.
Zai Lab Limited (NASDAQ: ZLAB) has commenced the Phase 3 ATTACK trial, evaluating the combination of sulbactam and durlobactam (SUL-DUR) against carbapenem-resistant Acinetobacter baumannii infections. This global trial includes around 300 patients and aims to address the rising incidence of these infections in China, where over 200,000 cases occur annually. The trial's data readout is anticipated in early 2021. The combination has shown positive in-vitro activity and safety in prior studies, marking a crucial step in combating multidrug-resistant infections.
Zai Lab has obtained marketing approval from the China National Medical Products Administration (NMPA) for Optune, a novel treatment for glioblastoma. This marks the first new treatment for glioblastoma in over 15 years in China. Clinical studies demonstrated that combining Optune with temozolomide more than doubled the five-year overall survival rate for newly diagnosed patients. The approval reinforces Zai Lab's position in the biopharmaceutical market, being its second product approval in six months.
Zai Lab (NASDAQ: ZLAB) announced that the Center for Drug Evaluation of China's NMPA has granted priority review status to its New Drug Application for omadacycline, targeting community-acquired bacterial pneumonia (CABP) and acute bacterial skin infections (ABSSSI). This designation aims to expedite the drug's approval process, addressing unmet medical needs in China related to bacterial resistance. Omadacycline, launched in the U.S. in February 2019, is designed to combat a broad range of bacterial infections, including multi-drug-resistant strains.
Summary not available.